Cargando…

Does cefiderocol heteroresistance explain the discrepancy between the APEKS-NP and CREDIBLE-CR clinical trial results?

Detalles Bibliográficos
Autores principales:	Choby, Jacob E, Ozturk, Tugba, Satola, Sarah W, Jacob, Jesse T, Weiss, David S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9743357/ https://www.ncbi.nlm.nih.gov/pubmed/35544102 http://dx.doi.org/10.1016/S2666-5247(21)00271-8

Ejemplares similares

LB16. Surveillance Rates of Cefiderocol Heteroresistance Correlate With All-cause Mortality in the APEKS-NP and CREDIBLE-CR Trials
por: Choby, Jacob E, et al.
Publicado: (2021)

Mechanisms of Reduced Susceptibility to Cefiderocol Among Isolates from the CREDIBLE-CR and APEKS-NP Clinical Trials
por: Nordmann, Patrice, et al.
Publicado: (2022)

Evidence for Efficacy of Cefiderocol against OXA-48-Containing Isolates from the APEKS-NP and CREDIBLE-CR Trials
por: Longshaw, Christopher, et al.
Publicado: (2022)

1266. Characterization of Shifts in Minimum Inhibitory Concentrations During Treatment with Cefiderocol or Comparators in the Phase 3 CREDIBLE-CR and APEKS-NP Studies
por: Takemura, Miki, et al.
Publicado: (2020)

Cefiderocol for the Treatment of Infections Due to Metallo-B-lactamase–Producing Pathogens in the CREDIBLE-CR and APEKS-NP Phase 3 Randomized Studies( )
por: Timsit, Jean Francois, et al.
Publicado: (2022)

Iron serum levels and iron homeostasis parameters in patients with nosocomial pneumonia treated with cefiderocol: post hoc analysis of the APEKS-NP study
por: Skaar, Eric P., et al.
Publicado: (2022)

P35 Heteroresistance to cefiderocol in clinical Gram-negative isolates
por: Watson, Celeste, et al.
Publicado: (2023)

Cefiderocol: Systematic Review of Mechanisms of Resistance, Heteroresistance and In Vivo Emergence of Resistance
por: Karakonstantis, Stamatis, et al.
Publicado: (2022)

Carbapenem-Resistant Klebsiella pneumoniae Exhibiting Clinically Undetected Colistin Heteroresistance Leads to Treatment Failure in a Murine Model of Infection
por: Band, Victor I., et al.
Publicado: (2018)

Theoretical Considerations and Empirical Predictions of the Pharmaco- and Population Dynamics of Heteroresistance
por: Levin, Bruce R., et al.
Publicado: (2023)

Comment on: Bacteraemia with an MBL-producing Klebsiella pneumoniae: treatment and the potential role of cefiderocol heteroresistance
por: Longshaw, Christopher M, et al.
Publicado: (2022)

2784. Rates of Susceptibility and Heteroresistance to Novel Antibiotic Combinations in Carbapenem-Resistant Enterobacterales Isolates - Emory Healthcare, 2016-2021
por: Lin, Christina K, et al.
Publicado: (2023)

165. Cefiderocol Treatment for Serious Infections Caused by Carbapenem-resistant Bacteria: Post-hoc Analysis of Outcomes by Pathogen in the CREDIBLE-CR Study
por: Matsunaga, Yuko, et al.
Publicado: (2020)

Colistin Heteroresistance Is Largely Undetected among Carbapenem-Resistant Enterobacterales in the United States
por: Band, Victor I., et al.
Publicado: (2021)

Induced Heteroresistance in Carbapenem-Resistant Acinetobacter baumannii (CRAB) via Exposure to Human Pleural Fluid (HPF) and Its Impact on Cefiderocol Susceptibility
por: Mezcord, Vyanka, et al.
Publicado: (2023)

1271. Efficacy and Safety of Cefiderocol and Best Available Therapy in Patients with Serious Infections Caused by Carbapenem-Resistant Gram-Negative Infections: Results of the Pathogen-Focused Phase 3 CREDIBLE-CR Study
por: Bassetti, Matteo, et al.
Publicado: (2020)

Aminoglycoside Heteroresistance in Acinetobacter baumannii AB5075
por: Anderson, Sarah E., et al.
Publicado: (2018)

Heteroresistance: A cause of unexplained antibiotic treatment failure?
por: Band, Victor I., et al.
Publicado: (2019)

Cefiderocol
por: Soriano, María Cruz, et al.
Publicado: (2022)

Antibiotic Heteroresistance in Klebsiella pneumoniae
por: Stojowska-Swędrzyńska, Karolina, et al.
Publicado: (2021)

Temporal discrepancies in “rapid” HIV testing: explaining misdiagnoses at the point-of-care in Zimbabwe
por: Skovdal, Morten, et al.
Publicado: (2023)

Explaining costly religious practices: credibility enhancing displays and signaling theories
por: Brusse, Carl, et al.
Publicado: (2022)

Pre-existing heterogeneity facilitates development of heteroresistance upon gene acquisition
por: Jaggavarapu, Siddharth, et al.
Publicado: (2023)

Reaction Kinetic Models of Antibiotic Heteroresistance
por: Martinecz, Antal, et al.
Publicado: (2019)

Detection of Pyrazinamide Heteroresistance in Mycobacterium tuberculosis
por: Werngren, Jim, et al.
Publicado: (2021)

Structured patient interview to assess clinical outcomes in complicated urinary tract infections in the APEKS-cUTI study: pilot investigation
por: Portsmouth, Simon, et al.
Publicado: (2021)

Does Exonerating an Accused Researcher Restore the Researcher’s Credibility?
por: Greitemeyer, Tobias, et al.
Publicado: (2015)

Heteroresistance to beta-lactam antibiotics may often be a stage in the progression to antibiotic resistance
por: Band, Victor I., et al.
Publicado: (2021)

Effects of CO-CR discrepancy in daily orthodontic treatment planning
por: COSTEA, CARMEN MARIA, et al.
Publicado: (2016)

Mutants with heteroresistance to amphotericin B and fluconazole in Candida
por: Claudino, A.L.R., et al.
Publicado: (2009)

Mechanisms of Heteroresistance and Resistance to Imipenem in Pseudomonas aeruginosa
por: Xu, Ye, et al.
Publicado: (2020)

Vancomycin heteroresistance in Staphylococcus haemolyticus: elusive phenotype
por: Bathavatchalam, Yamuna Devi, et al.
Publicado: (2021)

Fluoroquinolone heteroresistance, antimicrobial tolerance, and lethality enhancement
por: Singh, Amit, et al.
Publicado: (2022)

Quorum sensing regulates heteroresistance in Pseudomonas aeruginosa
por: Lu, Yang, et al.
Publicado: (2022)

Resolving colistin resistance and heteroresistance in Enterobacter species
por: Doijad, Swapnil Prakash, et al.
Publicado: (2023)

Clinical experience of cefiderocol
por: Fariñas, María Carmen
Publicado: (2022)

Mechanism of action of cefiderocol
por: Soriano, Alex, et al.
Publicado: (2022)

Cefiderocol. Summary and conclusions
por: Mensa, José, et al.
Publicado: (2022)

Antibacterial spectrum of cefiderocol
por: Cordero, Desirée Gijón, et al.
Publicado: (2022)

Credibility dilemmas under the Paris agreement: explaining fossil fuel subsidy reform references in INDCs
por: Elliott, Christian, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_p8aanala2vfqf1u8iv76tu9n9k